Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ACLX-001 + CART-ddBCMA |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ACLX-001 | ACLX001|ACLX 001 | TNFRSF17 Immune Cell Therapy 27 | ACLX-001 is a cell therapy comprising SPRX-001, a soluble protein targeting TNFRSF17 (BCMA), and Antigen Receptor Complex T-cells (ARC T-cells), which potentially induces antitumor activity (Cancer Res (2021) 81 (13_Supplement): 1549). | |
| CART-ddBCMA | Anitocabtagene autoleucel | TNFRSF17 Immune Cell Therapy 27 | CART-ddBCMA are autologous T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) with a synthetic antigen-binding domain targeting BCMA (TNFRSF17) and containing CD137 (4-1BB) and CD3 zeta signaling domains, which potentially have antitumor activity (PMID: 35468618). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|